HDAC6/HNF4α loop mediated by miR-1 promotes bile acids-induced gastric intestinal metaplasia

Na Wang1 · Min Chen1 · Zhen Ni1,2 · Ting Li1,3,4 · Jiaoxia Zeng1 · Guofang Lu1 · Jiaojiao Wang5 · Jian Zhang1 · Siran Wu1 · Yongquan Shi1

Abstract

Background Gastric intestinal metaplasia (IM) is considered a precancerous lesion, and bile acids (BA) play a critical role in the induction of IM. Ectopic expression of HNF4α was observed in a BA-induced IM cell model. However, the mechanisms underlying the upregulation of the protein in IM cells remains to be elucidated.

Methods The effects of HNF4α on gastric mucosal cells in vivo were identified by a transgenic mouse model and RNA-seq was used to screen downstream targets of deoxycholic acid (DCA). The expression of pivotal molecules and miR-1 was detected by immunohistochemistry and in situ hybridization in normal, gastritis and IM tissue slides or microarrays. The transcriptional regulation of HDAC6 was investigated by chromatin immunoprecipitation (ChIP) and luciferase reporter assays.

Results The transgenic mouse model validated that HNF4α stimulated the HDAC6 expression and mucin secretion in gastric mucosa. Increased HDAC6 and HNF4α expression was also detected in the gastric IM cell model and patient specimens. HNF4α could bind to and activate HDAC6 promoter. In turn, HDAC6 enhanced the HNF4α protein level in GES-1 cells. Furthermore, miR-1 suppressed the expression of downstream intestinal markers by targeting HDAC6 and HNF4α.

Conclusions Our findings show that the HDAC6/HNF4α loop regulated by miR-1 plays a critical role in gastric IM. Blocking the activation of this loop could be a potential approach to preventing BA-induced gastric IM or even gastric cancer (GC).

Keywords Gastric intestinal metaplasia · HDAC6 · HNF4α · CDX2 · Gastric cancer

Introduction

Gastric cancer (GC) is the third leading cause of cancer-related death worldwide [1]. Universally, the occurrence and stepwise development of intestinal gastric cancer (IGC) follow the Correa model: superficial gastritis–atrophic gastritis–metaplasia–hyperplasia–cancer [2, 3]. Early recognition and prevention of precancerous lesions may provide potential opportunities to prevent the appearance of GC.

Although a large number of studies have confirmed that intestinal metaplasia (IM) increases the risk of GC [4–7], the mechanisms underlying the initiation and progression of IM are poorly understood. In general, gastric IM is believed to be triggered or accelerated by some type of chronic environmental stimulus, such as Helicobacter pylori (Hp) infection, bile regurgitation, smoking and alcohol consumption [5, 8]. Although Hp infection is considered as the major cause of IM, whether the eradication of Hp could stop the development of GC remains controversial [9–11]. Therefore, other important factors may promote the occurrence of IM.
and GC. Reports have suggested that bile acids (BA) may have the potential to promote the transformation of cells and act as a tumor inducement in gastrointestinal neoplasia [12, 13]. Moreover, a high concentration of BA may promote the development of IM at the gastroesophageal junction of mice [14], and increases the extent and severity of IM is more serious in patients with high concentration of BA [15]. Therefore, additional attention should be focused on the pathogenic mechanisms of BA-induced gastric IM.

Caudal-related homeobox transcription factor 2 (CDX2) is an essential intestine-specific transcription factor (TF) [16, 17] that can modulate the transdifferentiation of IM by stimulating the transcription of intestinal markers, such as MUCIN 2 (MUC2), Krüppel-like factor 4 (KLF4), sucrase isomaltase (S-I) and VILLIN1 (VIL1) [18–20]. In recent years, researchers have focused on elucidating the regulatory mechanisms underlying the abnormal expression of these markers in the process of IM. Noticeably, hepatocyte nuclear factor-4α (HNF4α), which is a nuclear transcription factor highly expressed in the intestine that participates in regulating the development and function of the intestine, has recently been found to be associated with IM [21, 22]. In particular, Kojima et al. [23] found that HNF4α and MUC2 were overexpressed in IM and intestinal GC and are positively correlated. Similarly, we proved that the appearance of gastric IM was promoted by the transcriptional activation function of HNF4α on CDX2 after treatment with BA in vitro (manuscript submitted for publication). However, the activation mechanism of BA on HNF4α is not clear.

In this study, we found that BA caused a significant increase in histone deacetylase 6 (HDAC6) in the gastric cell line GES-1 through RNA-seq. Acetylation and deacetylation of histones are important epigenetic modifications that modulate gene transcription and expression. HDAC6, a special member of the HDAC family, not only participates in histone deacetylation but also acts on some nonhistone substrates to regulate cell metastasis, proliferation, and invasion in tumors [24, 25]. In addition, our previous study revealed that miR-1 was obviously decreased in a BA-induced gastric IM cell model [26]. Interestingly, we predicted through the mirWalk2.0 (https://zmf.unimuenster.de/apps/zmf/mirwalk2/), PicTar (https://pictar.mdc-berlin.de/) and Target scan (https://www.targetsca.org/vert_72/) databases that histone deacetylase 6 (HDAC6) had the same putative miR-1 3′-UTR binding sites as HNF4α. Therefore, we explored the relationship among miR-1, HDAC6 and HNF4α as well as their roles in BA-induced IM.

This study showed that BA led to an increase in HDAC6 and HNF4α by reducing the level of miR-1 and that the two proteins stimulated each other to form a positive loop and eventually caused gastric IM. Based on our results and relevant findings, we hypothesized that the loop regulates the molecular changes that occur with chronic bile regurgitation in gastric mucosa and promotes the progression of IM.

**Materials and methods**

**Cell lines**

GES-1, an immortalized gastric epithelial cell line, was used mainly to establish the IM model which was described previously [26]. AGS, MKN45 and AZ521 are gastric cancer cell lines. HCT-116 is one kind of colon cancer cell line. All of the cell lines were purchased from ATCC and resuscitated within 6 months and they were also tested negative for mycoplasma contamination. Gastric cells were cultured in PRIM-1640 medium (Gibco, US), while colon cells were cultured in DMEM medium (Gibco, US) and all cell lines were cultured with 10% fetal bovine serum (Biological Industries, Israel), 100 mg/ml streptomycin and 100 U/ml penicillin. Deoxycholic acid (DCA) is a major hydrophobic BA with strong cytotoxicity and it was purchased from Bio- cytoSci (USA).

**Tissue microarrays and human gastric IM samples**

A normal tissue microarray containing 24 cases (BN01011b) and a gastric IM tissue microarray (ST8017a) containing 80 cases were purchased from Alenabio Biotech (China). In addition, 24 normal cases, 15 gastritis cases, and 39 gastric IM cases were also included. Ten paired gastric IM specimens were obtained from patients who underwent endoscopy. To exclude the effect of Hp infection, all selected patients were Hp negative. All patients signed the informed consent forms before the specimens were obtained. Our study was approved by the Human Subjects Committee of Xijing Hospital. The pathological status of these specimens was collected from the Department of Pathology.

**Hnf4α transgenic mice**

The generation of Lgr5-Cre and LSL-Hnf4α mice were generated on a C57BL6 background. Lgr5-Cre mice were bred with LSL-Hnf4α mice to activate Hnf4α in gastric cells. To activate Cre recombinase in Rosa26R<sup>Hnf4α</sup> mice, the animals were intraperitoneally injected with 5 mg tamoxifen dissolved in corn oil once a day for three consecutive days at 4 weeks of age. The treatment, maintenance and care of mice in this study followed the protocols of the Animal Research Committee of Xijing Hospital.
Immunohistochemistry and in situ hybridization

Immunohistochemistry (IHC) was performed using anti-HDAC6 (1:400, Cell Signaling Technology, #7558) and anti-HNF4α (1:100, Abcam, #ab92378) following the manufacturer's instructions. In situ hybridization (ISH) was carried out by using a 5-digoxigenin (DIG) and 3'-DIG-labeled locked nucleic acid-based probe specific for miR-1 (Exiqon, Denmark) on tissue microarray. The IHC and ISH staining results were independently evaluated by two professional pathologists independently.

RNA extraction and real-time PCR

TRIzol® reagent (Invitrogen, USA) was used to extract the total RNA from cell lines and human tissue samples according to a standard protocol. Then RNA was reverse-transcribed into cDNA using the PrimeScript® RT Reagent kit (Takara Biotechnology, Japan) and qPCR was conducted using SYBR Premix Ex Taq II (Takara Biotechnology, Japan) on a CFX96™ Real-Time PCR Detection system (Bio-Rad Laboratories, USA). β-Actin and U6 were used as the internal control and the 2^ΔΔCq method was used to quantify the relative mRNA expression of each gene. Sequences of gene-specific primers are provided in Table 1.

Protein extraction and western blot analysis

Total protein was extracted by mixing cells with a radioimmunoprecipitation assay (RIPA) buffer (Beyotime, China) supplemented with protease and phosphatase inhibitors. Western blot analysis was carried out following standard procedures. The following antibodies were used for this experiment: anti-HDAC6 (1:1000, Cell Signaling Technology, #7558), anti-HNF4α (1:200, Abcam, #92378), anti-MUC2 (1:4000, Abcam, #ab133555), anti-KLF4 (1:1000, Cell Signaling Technology, #4038), anti-CDX2 (1:1000, Cell Signaling Technology, #12306), and anti-β-actin (1:5000, Bioworld, #AP0060). The primary antibody dilution buffer, PREstain Protein Ladder and Western SuperSensitive Substrate were purchased from BioCytoSci (USA).

Immunofluorescence cytochemistry

Immunofluorescence (IF) staining for HDAC6 and HNF4α was performed in GES-1 cells. The primary antibodies were a rabbit anti-human HDAC6 antibody (1:200, Cell Signaling Technology, #7558), a rabbit anti-human HNF4α antibody (1:200, Abcam, #92378), a rabbit anti-mouse LGR5 antibody (1:25, Abcam, #75732) and a mouse anti-mouse HNF4α antibody (1:50, Abcam, #374229).

Transfection

Synthetic miR-1 agomir, antagomir, the corresponding negative control oligonucleotides, plasmid and small interfering RNA (siRNA) were purchased from GenePharma (China), and their sequences are shown in Table 2. The transfection reagent was purchased from Thermo Fisher Scientific (USA) and used following the manufacturer’s protocol. HDAC6 and HNF4α overexpression lentiviral vectors were designed and provided by Genechem Co. Ltd. (China).

Dual-luciferase report assay

We amplified a 2000 bp sequence upstream of the transcription start sites of the HDAC6 promoter by PCR and then cloned it into a pGL3-basic luciferase vector (Invitrogen) to generate pHDAC6/2000-Luc, which was used to generate HDAC6-p1 (− 2000 to − 1 bp), HDAC6-p2 (− 1589 to − 1 bp), HDAC6-p3 (− 1544 to − 1 bp), HDAC6-p4 (− 1432 to − 1 bp) and HDAC6-p5 (− 1333 to − 1 bp). The 3’-UTR

| Table 1 | Sequence of primers used in the study |
|---------|--------------------------------------|
| Primer name | Forward sequence | Reverse sequence |
| HDAC6 | AGTCCATCGCGAGATACTGCC | TTAGTCTGCGCTGAGTGGGA |
| HNF4α | ACATGGACATGGCCGACTACA | AGCTGCAGAAAGCTGGGAT |
| miR-1 | TATAAGCTTTGCTCTGAGCTCGCTCTTCA | GTCCCGGGGTTCTGACATCAGAC |
| HDAC6 promoter | AAGATGTTTACTCTCTGTCCT | 

| Table 2 | Interference targets of each gene involved in the study |
|---------|--------------------------------------|
| siRNA name | Forward sequence | Reverse sequence |
| HDAC6 | AGTCCATCGCGAGATACTGCC | TTAGTCTGCGCTGAGTGGGA |
| HNF4α | ACATGGACATGGCCGACTACA | AGCTGCAGAAAGCTGGGAT |
| miR-1 agomir | UGGAUAGUAAGAAGAUGAUAA | ACAUCUUCUCUUUACAUUCAUU |
| miR-1 antagomir | AUACAUACUUCUUCUACAUUCAUU |
Figure 1: HNF4α-induced gastric mucosal changes in mice. a) Schematic of the gene constructs for Lgr5-Cre mice and LSL-Hnf4α mice, and the experimental strategy for Cre-mediated recombination in the Rosa26Hnf4α mice. b) Representative electron microscopy pictures showing mucin of Rosa26Hnf4α mice gastric epithelium (arrows). Scale bar: 2 µm. c) Immunohistochemistry (IHC) for Hnf4α in the stomach section of WT and Rosa26Hnf4α mice. The right boxes indicate regions enlarged. Scale bars: 200 µm (left); 50 µm (right). d) HE staining for gastric sections of WT and Rosa26Hnf4α mice. Scale bars: 100 µm. e) Different sections from WT and Rosa26Hnf4α mice were examined by Alcian blue staining–periodic acid–Schiff (AB–PAS) staining. Scale bars: 1000 µm (left); 50 µm (right).

Results

HNF4α overexpression in the mouse stomach promotes mucin secretion

To better understand the prometaplastic role of Hnf4α in vivo, we constructed an Hnf4α transgenic mouse model that expresses the active form of Hnf4α in Lgr5+ gastric stem cells upon tamoxifen exposure (Figs. 1a, S1). The mice were killed and gastric tissues were separated after tamoxifen treatment for 0, 6 and 12 months, respectively. We found that the gastric mucosa of wild-type (WT) mice and Rosa26Hnf4α mice were both mostly normal at 0 and 6 months (data not shown). Nevertheless, compared with that of WT mice, at 12 months post-tamoxifen, the expression level of Hnf4α in gastric tissues was significantly higher and structural abnormalities were observed in the gastric mucosa of Rosa26Hnf4α mice (Fig. 1c, d). More importantly, electron microscopy studies revealed that mucin increased in the gastric cells of Rosa26Hnf4α mice (Fig. 1b). Further, AB-PAS staining showed obvious positive staining in the fovea of gastric mucosa and the bottom of glands in Rosa26Hnf4α mice, while weak staining was found only in the pits in WT mice (Fig. 1e). Although no obvious IM cells were observed in the gastric mucosa of mice, these changes may still indicate that Hnf4α might affect the development of gastric mucosa and promote the secretion of intestinal mucus.

Chromatin immunoprecipitation

GES-1 cells were transiently transfected with an HDAC6 promoter vector. Then, chromatin immunoprecipitation (ChIP) analysis was carried out according to the standard method of the Magna ChIP G Assay kit (EMD Millipore, USA). Chromatin was immunoprecipitated with anti-HNF4α (Abcam, #ab181604) or IgG as a negative control. Finally, immunoprecipitated DNA–protein complexes were isolated and a real-time PCR assay was carried out to examine the quantity of the specific proteins. The primers for the HDAC6 promoters are listed in Table 1.

Statistical analysis

The SPSS software (V.19.0, SPSS, Chicago, Illinois, USA) statistical package was used to conduct all statistical analyses. All continuous data are expressed as the mean ± SD. The χ2 test was used to compare the frequencies of categorical variables. Mutual associations among clinical results were assessed by using Spearman’s rank correlation. Statistical comparisons between two groups were analyzed by the Mann–Whitney U test. Multiple comparisons were performed via a one-way analysis of variance (ANOVA) with the Bonferroni post hoc test. P values less than 0.05 were considered statistically significant.

Expression of HDAC6 in IM tissues and its correlation with HNF4α

To investigate the relevance of HDAC6 and HNF4α with gastric IM clinically, we examined the expression of both in normal, gastritis and IM tissues (Fig. 3a, b). Both HDAC6 and HNF4α increased in IM tissues, and the number of samples showing high expression was greater than that showing low or moderate expression in gastric IM tissues (Fig. 3c-e). Additionally, negative expression of HDAC6 and HNF4α were mainly observed in normal tissues, while
positive expression was mostly observed in gastric IM tissues (HDAC6: 85/119, 71.4%, $P = 0.0302$; HNF4α: 102/119, 85.7%, $P < 0.0001$). The correlation analysis showed that the expression levels of HDAC6 in IM tissues were positively associated with HNF4α (Fig. 3f and Table 3). Consistently, the staining results of tissue microarrays indicated that most of the HDAC6-positive tissues were also positive for HNF4α (Fig. 3f and Table 3). Overlapping expression of the two molecules was seen in 80.67% (96/119) of IM tissues, which further suggested a close correlation between HDAC6 and HNF4α (Fig. 3g and Tables 4, 5). Moreover, as shown in Fig. 3h, the mRNA level of both is higher in IM tissues than in normal tissues. In summary, these findings imply a potential prometaplastic role of HDAC6 and HNF4α in human gastric tissues.

**HDAC6 is transcriptionally activated by HNF4α in gastric cells**

To further study the role of HDAC6 in IM, we performed gain-of-function and loss-of-function experiments. First, we infected GES-1 cells with an HDAC6 overexpression vector, and the results showed that the upregulation of HDAC6 caused an increase of CDX2, KLF4 and MUC2 protein levels (Fig. 4a). Subsequently, AGS cells, which highly express HDAC6 and HNF4α, were transfected with HDAC6-specific
siRNA and the results revealed that the downregulation of HDAC6 inhibited the expression of downstream intestinal markers (Fig. 4b). Further, we investigated the regulatory effect of HNF4α on HDAC6 and found that HNF4α overexpression caused a significant increase in HDAC6 in GES-1 cells (Fig. 4c), while siHNF4α resulted in a decrease in

Table 3 Correlation between HDAC6 and HNF4α in IM tissues

|       | HDAC6 | HNF4α | Correlation |
|-------|-------|-------|-------------|
|       |       |       | r       | p         |
| Positive | 85    | 102   | 0.4621  | 0.0001   |
| Negative | 34    | 17    |          |          |
HDAC6 in AGS cells, which indicated that HNF4α could positively regulate the expression of HDAC6 in gastric cells (Fig. 4d). Interestingly, HDAC6 was found to also have a positive regulatory effect on HNF4α, which may lead to the formation of a positive feedback regulatory loop. The loop is still effective in the presence of BA as shown in Fig. 4e because both siHDAC6 and siHNF4α could reverse the upregulation of each other and intestinal markers triggered by DCA. Next, to reveal the regulatory mechanism of HNF4α on HDAC6, the JASPAR (https://jaspar.binf.ku.dk/) and PROMO (https://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3) databases were used to predict whether HNF4α had a transcription binding site in the HDAC6 promoter region. Then we constructed the reporter genes for truncated bodies containing different HDAC6 binding sites according to the predicted results of JASPAR and cotransfected them with the HNF4α expression vector in GES cells (Table 1). The data showed that the activity of HDAC6-p4 plasmids increased most obviously, suggesting that the sequence (−1432 to −1332 bp) might be the active fragment of HNF4α on the HDAC6 promoter (Fig. 4f). The ChIP assays further verified that HNF4α could combine with the HDAC6 promoter (AGGATCAGAGGGCAA), and this combination was strengthened under DCA (Fig. 4j, h). Additionally, Hdad6 was found to be enhanced by Hnf4α in Rosa26Hnf4α mice and both were mainly located at the bottom of the gland in the gastric antrum (Fig. 4i). In summary, these results indicated that HDAC6 positively regulated intestinal markers and HNF4α and showed that HNF4α could transcriptionally activate HDAC6 in gastric cells.

Expression of miR-1 in IM cells

All the above results indicated that DCA promotes the development of IM through a closed HDAC6/HNF4α loop, although the role of BA in this signaling pathway remains unclear. In a previous study, we sequenced microRNA in GES-1 cells after BA treatment [26]. Combined with a bioinformatics analysis, we found that among several micro-RNAs that were significantly reduced, miR-1 might be closely related to this loop (Fig. 5a). We speculated that miR-1 might target HDAC6 and HNF4α posttranslationally in IM cells. As expected, the treatment with DCA led to an obvious decrease in miR-1 in GES-1, MKN45 and AZ521 cells (Fig. 5b), and similar results were observed in primary cells post-DCA (Fig. 5c). Furthermore, we found that the level of miR-1 in gastric IM tissues was markedly lower than that in peripheral normal tissues (Fig. 5d). Additionally, microarray in situ hybridization showed that the level of miR-1 in IM was obviously lower than that in normal tissues and the location of miR-1 was in the cytoplasm and nucleus (Fig. 5e). Moreover, the staining indicated that the expression level of miR-1 in IM was remarkably lower than that of HDAC6 or HNF4α and miR-1 was negatively correlated with HDAC6 and HNF4α (Figure S3A, S3B). Collectively, these data suggest that miR-1 decreased in IM tissues and BA-induced IM cells.

MiR-1 suppresses HDAC6/HNF4α loop and intestinal markers

To confirm that miR-1 could target HDAC6 and HNF4α, we treated GES-1 cells with a concentration gradient of anti-miR-1. We found that 200 nM anti-miR-1 remarkably reduced the level of miR-1 (Fig. 6a). Then, we used 200 nM
anti-miR-1 to transfect GES-1 and BGC-823 cells, and found a robust enhancement of HDAC6 and HNF4α levels accompanied by an increase in intestinal markers (Fig. 6b). Moreover, we transfected AGS and BGC-823 cells with ago-miR-1 and observed that 100 nM ago-miR-1 caused an obvious increase in miR-1 (Fig. 6c). Additionally, HDAC6 and HNF4α decreased substantially with the reduction of CDX2, KLF4 and MUC2 after transfection (Fig. 6d), which is similar to the results from HDAC6 or HNF4α downregulation. These results suggest that the expression of miR-1 could inversely affect the expression levels of HDAC6 and HNF4α. To show that the regulation of the two molecules by miR-1 is achieved by acting on their 3′-UTRs, we carried out luciferase reporter assays (Fig. 6e, 6f). In the GES-1 and BGC-823 cells, the activity of the HDAC6 wt3′-UTR was decreased by miR-1 restoration, while the HDAC6 mut3′-UTR with a mutated binding site sequence was not affected by miR-1. Similarly, the activity of the HNF4α wt3′-UTR was also significantly inhibited by miR-1 (Fig. 6g, h). A quantitative protein analysis showed that HDAC6 levels increased in cells transfected with the W7 or mutant HDAC6 plasmids, but were attenuated in cells cotransfected with the WT HDAC6 and miR-1 (Fig. 6i). Similarly, cotransfection of both HNF4α and miR-1 did not cause an increase in HNF4α (Fig. 6j). In addition, miR-1 attenuated the activation of HDAC6 and HNF4α by DCA (Figure S3C), which indicated that miR-1 is crucial in this process. Our findings demonstrate that the ectopic expression of HDAC6 and HNF4α induced by BA occurs mainly via miR-1 silencing.

**Discussion**

This study determined that the BA-induced loop, involving HDAC6 and HNF4α is posttranscriptionally inhibited by miR-1 in BA-induced IM. HNF4α directly targets HDAC6, while miR-1 directly regulates HDAC6 and HNF4α in gastric cells. Hence, the loop which is modulated by miR-1 plays an important role in gastric IM triggered by BA.

At present, the occurrence of IM is believed to involve the abnormal expression of some intestinal markers in gastric mucosa. Reports have indicated that the ectopic expression of CDX2 in the esophagus and gastric mucosa of mice could successfully induce IM [27, 28]. Moreover, BA has been shown to induce the expression of CDX2 in esophageal epithelial cells and then Barrett’s esophagus (BE) cells [29]. However, the mechanism underlying the initiation of gastric IM stimulated by BA is still unclear. Previously, we observed that BA could increase CDX2 and induce the IM phenotype through the miR-92a/FOXD1/NF-κB axis, SOX2/CDX2 complex or FXR/SHP axis in GES-1 cells [28, 30, 31]. Herein, we further confirmed in vivo that HNF4α can cause an abnormal morphology of gastric mucosa and led to the secretion of intestinal mucus and we also found that it could interact with HDAC6 to promote the expression of intestinal markers. However, our understanding of aberrant HNF4α expression in IM cells remains unclear.

The miRNA array showed that BA remarkably inhibits miR-1, and the miR-1 sequence is bioinformatically predicted to bind to the 3′-UTR of HNF4α. Similarly, miR221/222 and miR-92a are upregulated by BA in esophageal tissues and in gastric cells, respectively, suggesting that miRNAs may serve as an inevitable role in BA-triggered IM [32]. However, direct evidence of the relationship between miR-1 and IM or BA is lacking. HDAC6 has been predicted to have the same binding sequence to miR-1 as HNF4α. We showed for the first time that silencing miR-1 in gastric cells led to the activation of the two targets and the downstream intestinal markers. Once the level of miR-1 was negatively regulated by BA, the loop will be triggered and continue to occur.

Numerous studies have found that HDAC6 could stimulate tumor progression by promoting tumor cell transformation [33, 34], thereby facilitating tumor proliferation [35–37], and regulating tumor immunity [38–41]. In addition, HDAC6 was dramatically increased in Hp-positive gastric IM and GC tissues, suggesting that it may have a definite correlation with IM [42]. Sandeep Akare et al. discovered that BA could maintain chromosome stability, and they stimulated cell differentiation by inducing HDAC6 expression in colon cancer cells, which implies that there is a correlation between BA and HDAC6 [43]. Our study not only reconfirmed the activation of BA on HDAC6, but also clarified the prometaplastic function of HDAC6 in BA-induced gastric IM. In this process, HNF4α binds to the HDAC6 promoter and activates its transcription. Moreover, HDAC6 could stimulate the expression of HNF4α to form a closed loop.

We also attempted to determine whether DCA augmented HDAC6 and HNF4α expression in primary gastric cells of mice, and the results were similar to that in gastric cell lines. Above all, our mouse model reaffirmed that HNF4α could augment HDAC6 expression and showed that HDAC6 and HNF4α were both responsible for the induction of mucin secretion in gastric cells. However, typical intestinal metaplasia cells were not observed in the gastric mucosa of transgenic mice, and we will continue to observe the changes of gastric mucosa in subsequent experiments. Moreover, the effects of BA on HDAC6 and HNF4α have not been tested in vivo; thus further studies are required. Despite the deficiencies, this study clearly indicated that forced expression of HNF4α and HDAC6 in gastric epithelial cells promotes a
HDAC6/HNF4α loop mediated by miR-1 promotes bile acids-induced gastric intestinal metaplasia

A series of molecular changes, followed by the appearance of IM cells. These findings are helpful for better understanding the underlying mechanisms of BA-induced gastric IM. Collectively, our findings demonstrate for the first time that BA causes the high expression of HDAC6 and HNF4α as well as the low expression of miR-1 in gastric cells (Fig. 6k) and both HDAC6 and HNF4α could facilitate the expression of each other. More importantly, miR-1, which is downregulated in IM cells, inhibited both HDAC6 and HNF4α by directly binding to their 3′-UTR.

In summary, our study revealed a new HDAC6/HNF4α loop regulated by miR-1, which is helpful for further elucidating the underlying mechanism of gastric IM. Suppression of the HDAC6/HNF4α loop and restoration of miR-1 may be a promising approach for gastric IM in patients with bile reflux.
Fig. 6 miR-1 downregulated HDAC6 and HNF-4α by directly binding its 3′-UTR. a, b Downregulated expression of miR-1 led to downregulated protein expression of HDAC6, HNF-4α and intestinal markers. c, d Upregulated expression of miR-1 resulted in the opposite changes. e, f A schematic representation of the HDAC6 and HNF-4α 3′-UTR. Mutations were generated at the predicted miR-1-binding sites. g, h miR-1 luciferase reporter assay. A luciferase reporter was fused with the wild-type or mutant miR-1 targets (HDAC6 and HNF-4α), and then transfected into mock-infected or miR-1-infected GES-1 and BGC-823 cells. The luciferase activity of the wild-type luciferase reporters were suppressed by miR-1 significantly. i, j GES-1 cells were transfected with wild-type and mutant miR-1 targets (HDAC6, HNF-4α), along with miR-1. HDAC6, HNF-4α and intestinal markers expression were detected by immunoblots. k A schematic model of miR-1/HDAC6/HNF-4α pathway in gastric cells. Induced by specific concentrations of bile acid, silenced miR-1 stimulates the expression of HDAC6 and HNF-4α to activate downstream intestinal markers.

*P < 0.05; **P < 0.01. N.S. not significant

Acknowledgements This study was supported in part by Shaanxi Innovation Promotion Project, Grant number 2018TD-003 (to YQS). We wish to thank Zhang Lifeng, Fenli Zhou, Yong Guo and Dr Wu qiong (Xijing Hospital of Digestive Diseases) for technical assistance.

Author contributions All authors included in this paper fulfill the criteria of authorship and have approved the submission of this manuscript. NW and YQS designed the experiments. NW, MC, ZN, TL, JXZ, GFL, JJW, JZ and SRW performed the study. YQS supervised the study.

Funding This work was supported by grants from National Natural Science Foundation of China (no. 81873554 to YQS).

Data availability All data generated or analyzed during this study are included in this manuscript.

Compliance with ethical standards

Conflict of interest The authors declare no potential conflicts of interest.

Ethics approval All human studies were approved by the Human Subjects committee of Xijing Hospital, Xi’an China. All animal experiments were approved by the Animal Research Committee of Xijing Hospital, Xi’an China.

Informed consent All patients signed the informed consent before the specimens were obtained.

Consent for publication All authors have agreed to publish this manuscript.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
2. Sue S, Shibata W, Maeda S. Helicobacter pylori-induced signaling pathways contribute to intestinal metaplasia and gastric carcinogenesis. Biomed Res Int. 2015;2015:737621.
3. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process—first American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52:6735–40.
4. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9.
5. Li D, Bautista MC, Jiang SF, Daryani P, Brackett M, Armstrong MA, et al. Risks and predictors of gastric adenocarcinoma in patients with gastric intestinal metaplasia and dysplasia: a population-based study. Am J Gastroenterol. 2016;111:1104–13.
6. de Vries AC, Meijer GA, Looman CW, Casparie MK, Hansen BE, van Grieven NC, et al. Epidemiological trends of pre-malignant gastric lesions: a long-term nationwide study in the Netherlands. Gut. 2007;56:1665–700.
7. de Vries AC, van Grieven NC, Looman CW, Casparie MK, de Vries E, Meijer GA, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology. 2008;134:945–52.
8. Choi AY, Strate LL, Fix MC, Schmidt RA, Ende AR, Yeh MM, et al. Association of gastric intestinal metaplasia and East Asian ethnicity with the risk of gastric adenocarcinoma in a U.S. population. Gastrointest Endosc. 2018;87:1023–8.
9. Jiang JX, Liu Q, Zhao B, Zhang HH, Sang HM, Djaleel SM, et al. Risk factors for intestinal metaplasia in a southeastern Chinese population: an analysis of 28,745 cases. J Cancer Res Clin Oncol. 2017;143:409–18.
10. Leung WK, Lin SR, Ching JY, To KF, Ng EK, Chan FK, et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut. 2004;53:1244–9.
11. Lee YC, Chen TH, Chiu HM, Shun CT, Chiang H, Liu TY, et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut. 2013;62:676–82.
12. Reddy BS, Sharma C, Simi B, Engle A, Laakso K, Puska P, et al. Metabolic epidemiology of colon cancer: effect of dietary fiber on fecal mutagens and bile acids in healthy subjects. Cancer Res. 1987;47:644–8.
13. Kaur BS, Ouatu-Lascar R, Ormay MB, Triadafilopoulos G. Bile salts induce or blunt cell proliferation in Barrett’s esophagus in an acid-dependent fashion. Am J Physiol Gastrointest Liver Physiol. 2000;278:G1000–G10091009.
14. Debruyne PR, Witek M, Gong L, Birbe R, Chervoneva L, Jinn T, et al. Bile acids induce ectopic expression of intestinal guanylyl cyclase C Through nuclear factor-kappaB and Cdx2 in human esophageal cells. Gastroenterology. 2006;130:1191–206.
15. Tsutsumi M, Ito M, Tanaka S, Yoshihara M, Matsui H, Haruma K, et al. Bile acid promotes intestinal metaplasia and gastric carcinogenesis. Cancer Epidemiol Biomark Prev. 2012;21:2101–7.
16. Silberg DG, Swain GP, Suh ER, Traber PG. Cdx1 and Cdx2 expression during intestinal development. Gastroenterology. 2000;119:961–71.
17. Guo RJ, Suh ER, Lynch JP. The role of Cdx proteins in intestinal development and cancer. Cancer Biol Ther. 2004;3:593–601.
18. Barros R, Freund JN, David L, Almeida R. Gastric intestinal metaplasia revisited: function and regulation of CDX2. Trends Mol Med. 2012;18:565–63.
19. Reis CA, David L, Correa P, Carneiro F, de Bolos C, Garcia E, et al. Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression. Cancer Res. 1999;59:1003–7.
20. Furumiy M, Inoue K, Ohta K, Hayashi Y, Yuasa H. Transcriptional regulation of PCFT by KLF4, HNF4alpha, CDX2 and C/EBPalpha: implication in its site-specific expression in the small intestine. Biochem Biophys Res Commun. 2013;431:158–63.
21. Torres-Padilla ME, Fougere-Deschatrette C, Weiss MC. Expression of HNF4alpha isoforms in mouse liver development is regulated by sequential promoter usage and constitutive 3’ end splicing. Mech Dev. 2001;109:183–93.
22. Watt AJ, Garrison WD, Duncan SA. HNF4a: a central regulator of hepatocyte differentiation and function. Hepatology. 2003;37:1249–53.
23. Kojima K, Kishimoto T, Nagai Y, Tanizawa T, Nakatani Y, Miyazaki M, et al. The expression of hepatocyte nuclear factor-4alpha, a developmental regulator of visceral endoderm, correlates with the intestinal phenotype of gastric adenocarcinomas. Pathology. 2006;38:548–54.
24. Zhang X, Yuan Z, Zhang Y, Yong S, Salas-Burgos A, Leong AS. CDX2 and villin are used in transgenic mice. Gastroenterology. 2002;119:2958–69.
25. Aoyagi S, Archer TK. Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends Cell Biol. 2005;15:565–7.
26. Li T, Guo H, Li H, Jiang Y, Zhuang K, Lei C, et al. MicroRNA-200a-1-5p increases CDX2 by targeting FOXD1 in bile acids-induced gastric intestinal metaplasia. Gut. 2019;68:1751–63.
27. Silberg DG, Sullivan J, Kang E, Swain GP, Moffett J, Sund NJ, et al. Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology. 2002;122:689–96.
28. Shi XY, Bhagwandeon B, Leong AS. CDX2 and villin are useful markers of intestinal metaplasia in the diagnosis of Barrett esophagus. Am J Clin Pathol. 2008;129:571–7.
29. Kazumori H, Ishihara S, Rumi MA, Kadowaki Y, Kinoshita Y. Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in Barrett’s epithelium. Gut. 2006;55:16–25.
30. Yuan T, Ni Z, Li T, Sun L, Zhang L, Liu N, et al. SOX2 interferes with the function of CDX2 in bile acid-induced gastric intestinal metaplasia. Cancer Cell Int. 2019;19:24.
31. Zhou H, Ni Z, Li T, Su L, Zhang L, Liu N, et al. Activation of FXR promotes intestinal metaplasia of gastric cells via SHP-dependent upregulation of the expression of CDX2. Oncol Lett. 2018;15:7617–24.
32. Matsuzaki J, Suzuki H, Tsugawa H, Watanabe M, Hossain S, Arai E, et al. Bile acids increase levels of microRNAs 221 and 222, leading to degradation of CDX2 during esophageal carcinogenesis. Gastroenterology. 2013;145:1300–11.
33. Salemi LM, Maenetland Y, Jefter ER, Schild-Poulter C. Inhibition of HDAC6 activity through interaction with RanBP1 and its associated CTLH complex. BMC Cancer. 2017;17:460.
34. Putcha F, Yu J, Rodriguez-Barrueco R, Sauedco-Cuevas L, Villagrasa P, Muga-Penas E, et al. HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. Breast Cancer Res. 2015;17:149.
35. Li D, Sun X, Zhang L, Yan B, Xie S, Liu R, et al. Histone deacetylase 6 and cytoplasmic linker protein 170 function together to regulate the motility of pancreatic cancer cells. Protein Cell. 2014;5:214–23.
36. Lee YS, Lim KH, Guo X, Kawaguchi Y, Gao Y, Barrientos T, et al. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res. 2008;68:7561–9.
37. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets? Cancer Lett. 2009;277:8–21.
38. Cheng F, Lienlaf M, Perez-Villarroel P, Wang HW, Lee C, Woan K, et al. Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells. Mol Immunol. 2014;60:44–53.
39. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–71.
40. Shimizu T, Seto T, Hirai F, Takenoyama M, Nosaki K, Tsurutani J, et al. Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. Invest New Drugs. 2016;34:347–54.
41. Hao M, Zhao G, Du X, Yang Y, Yang J. Clinical characteristics and prognostic indicators for metastatic melanoma: data from 446 patients in north China. Tumour Biol. 2016;37:10339–48.
42. Wang F, Luo LD, Pan JH, Huang LH, Lv HW, Guo Q, et al. Comparative genomic study of gastric epithelial cells co-cultured with Helicobacter pylori. World J Gastroenterol. 2012;18:7212–24.
43. Akare S, Jean-Louis S, Chen W, Wood DJ, Powell AA, Martinez JD. Ursodeoxycholic acid modulates histone acetylation and induces differentiation and senescence. Int J Cancer. 2006;119:2958–69.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.